People: Ligand Pharmaceuticals Inc (LGND.O)

LGND.O on Consolidated Issue listed on NASDAQ Global Market

91.94USD
31 Aug 2015
Change (% chg)

$-3.10 (-3.26%)
Prev Close
$95.04
Open
$94.86
Day's High
$96.59
Day's Low
$91.72
Volume
235,790
Avg. Vol
424,367
52-wk High
$112.40
52-wk Low
$41.99

Search Stocks

Sabba, Stephen 

Dr. Stephen L. Sabba, M.D., serves as an Independent Director of Ligand Pharmaceuticals Inc., August 4, 2008. Dr. Sabba has been a leading Bio/Pharma Analyst and Fund Manager for Knott Partners, L.P., an investment fund company, since November 2006. Previously he was a Partner and Director of Research with Kilkenny Capital Management, a Chicago-based biomedical hedge fund. Prior to that, Dr. Sabba was Director of Research at Sturza’s Medical Research, and previously was a gastroenterologist and internist in private practice at Phelps Memorial Hospital in North Tarrytown, New York. He received his medical degree from the New York University School of Medicine, and completed a residency in internal medicine and a fellowship in gastroenterology at the Veterans Administration Medical Center in New York City. He earned a Bachelor of Science degree with honors at Cornell University. Dr. Sabba has served as a member of the board of the directors for QLT, Inc., a leading Canadian biotech company, since June 2012. In selecting Dr. Sabba to serve as a director, the board considered, among other things, his capital markets and accounting expertise gained from his prior experience working in the hedge fund and investment fund industries. Ligand also benefits from his background as a medical doctor and from his understanding of medicine.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

John Kozarich

--

Matthew Foehr

4,055,940

John Higgins

6,047,260

Matthew Korenberg

--

Charles Berkman

1,554,920

Jason Aryeh

--
As Of  30 Dec 2014
Search Stocks